Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical NK Cells with Pemetrexed in Stage IV NSCLC
NCT03366064Phase 1Completed
- Sponsor
- Asan Medical Center
- Start
- Nov 2017
- Primary completion
- Sep 2018
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of haploidentical natural killer cells in non-small cell lung cancer (NSCLC), sponsored by Asan Medical Center. Primary endpoint: Maximum Tolerated Dose at 6 weeks. Started Nov 2017; status: completed.
02
Drugs
haploidentical natural killer cells
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03366064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03366064.